1. Ageing, and Treatment of Hypertension

   • J. I. S. Robertson

   Section 1 18 October 2012 Pages: 1 - 6

2. The Therapeutic Dilemma of Hypertension in the Elderly

   • Stevo Julius

   Section 1 18 October 2012 Pages: 7 - 17

3. Comparative Double-Blind Study of Ketanserin versus Propranolol in the Treatment of Essential Hypertension

   • K. Ito
   • T. Omae
   • K. Tanaka

   Section 1 18 October 2012 Pages: 18 - 24

4. Effects of Ketanserin Tartrate on Serum Lipids in Patients with Essential Hypertension

   • H. Nakamura
   • F. Hirata
   • I. Takeuchi

   Section 1 18 October 2012 Pages: 25 - 34

5. Ketanserin in the Treatment of Diabetes-Associated Hypertension

   • Carlo Beretta-Piccoli

   Section 1 18 October 2012 Pages: 35 - 43

6. Ageing, Serotonin and Ketanserin

   • Alasdair Breckenridge

   Section 2 18 October 2012 Pages: 44 - 54

7. Interference of Ketanserin with Baroreflex Control of the Circulation in the Conscious Spontaneously Hypertensive Rat

   • J. Smits
   • F. van Dorsten
   • H. A. J. Struyker Boudier

   Section 2 18 October 2012 Pages: 55 - 60

8. Serotonin Metabolism and Age-Related Effects of Antihypertensive Therapy with Ketanserin

   • Ruth Amstein
   • Natalia Fetkovska
   • Fritz R. Bühler

   Section 2 18 October 2012 Pages: 61 - 66

9. The Relevance of Serotonin Antagonism in the Treatment of Hypertension

   • A. E. Doyle

   Section 2 18 October 2012 Pages: 67 - 73

10. Arterial Dilatation and Venous Constriction Induced by Serotonin in the Elderly

    • G. J. Blauw
    • P. van Brummelen
    • P. A. van Zwieten

    Short Communication 18 October 2012 Pages: 74 - 77

11. Serotonin and Platelet Aggregation in Patients with Essential Hypertension Compared with a Normotensive Control Group

    • David J. Stott
    • Abbey R. Saniabadi
    • Stephen G. Ball

    Short Communication 18 October 2012 Pages: 78 - 82

12. Role of Endogenous Serotonin in the Regulation of Blood Pressure in Patients with Chronic Renal Failure

    • Minoru Yamakado
    • Masashi Nagano
    • Hiroshi Kiyose

    Short Communication 18 October 2012 Pages: 83 - 86

13. Hyperreactivity of Platelets to Serotonin (5-Hydroxytryptamine) in Patients with Cardiovascular Diseases

    • Jean De Crée
    • Vera Roels
    • Herman Verhaegen

    Short Communication 18 October 2012 Pages: 87 - 91

14. Effects of Long Term Oral Administration of Ketanserin and Trichlormethiazide on Blood Pressure in Stroke-Prone Spontaneously Hypertensive Rats

    • Masaru Minami
    • Naoya Hamaue
    • Hideya Saito

    Short Communication 18 October 2012 Pages: 92 - 96

15. Inhibitory Effect of Ketanserin on Sympathetic Nerve Activity in Rats

    • Mitsuhiro Yoshioka
    • Matsumoto Machiko
    • Hideya Saito

    Short Communication 18 October 2012 Pages: 97 - 101

16. Contribution of Serotonergic Systems to Maintenance of Blood Pressure in Anaesthetised Normotensive Wistar Kyoto and Conscious Spontaneously Hypertensive Rats

    • B. -G. Schulz
    • G. Schröder
    • G. Stock

    Short Communication 18 October 2012 Pages: 102 - 104

17. A New Selective Antagonist of Vascular Serotonin Receptors Lowers Blood Pressure in Spontaneously Hypertensive Rats

    • P. Salvati
    • F. Vaghi
    • G. Bianchi

    Short Communication 18 October 2012 Pages: 105 - 109

18. Antihypertensive Effect of Long Term Ketanserin in Elderly Essential Hypertensive Patients

    • R. A. Sánchez
    • F. Otero
    • E. J. Marcó

    Short Communication 18 October 2012 Pages: 110 - 113

19. Pharmacokinetic Properties of Ketanserin in Man with Normal or Reduced Renal Function after Single Dose Oral Administration

    • Kaoru Onoyama
    • N. Ouchi
    • S. Koboyashi

    Short Communication 18 October 2012 Pages: 114 - 114

20. Haemodynamic Changes Associated with Long Term Antihypertensive Therapy with Ketanserin

    • Hiroshi Noda
    • Masaaki Isaka
    • Toshiro Fujita

    Short Communication 18 October 2012 Pages: 115 - 119

21. Effects of Ketanserin on Systemic and Regional Haemodynamics in Patients with Essential Hypertension

    • Yasushi Ito
    • Masaaki Isaka
    • Toshiro Fujita

    Short Communication 18 October 2012 Pages: 120 - 122

22. Influence of Ketanserin on Glucose and Lipid Metabolism in Diabetic Patients with Hypertension

    • H. U. Janka
    • H. Mehnert
    • K. -U. Seiler

    Short Communication 18 October 2012 Pages: 123 - 125

23. Effect of Ketanserin on Lipoproteins in Patients with Essential Hypertension

    • K. Arakawa
    • Jun Sasaki
    • H. Doi

    Short Communication 18 October 2012 Pages: 126 - 129

24. Comparative Trial of Ketanserin or Bendrofluazide as Add-On Therapy in Hypertensive Patients Uncontrolled on a β-Blocker Alone

    • K. Korlipara
    • Susan E. Gould
    • T. C. Chandler

    Short Communication 18 October 2012 Pages: 130 - 134

25. Ketanserin, an Effective Third-Line Agent in Primary Hypertension

    • J. J. Murphy
    • P. H. Whincup
    • R. G. Wilcox

    Short Communication 18 October 2012 Pages: 135 - 139

26. Comparative Study of Ketanserin and Hydrochlorothiazide in Essential Hypertension

    • I. W. Bayman
    • Susan E. Gould
    • The Janssen Research Group

    Short Communication 18 October 2012 Pages: 140 - 143

27. Comparison of Ketanserin with Captopril in Older Hypertensives

    • P. Meyer
    • M. Safar

    Short Communication 18 October 2012 Pages: 144 - 147

28. Hypertensive Patients with Raynaud’s Phenomenon or Intermittent Claudication and Their Treatment with Ketanserin

    • J. C. van Oene

    Short Communication 18 October 2012 Pages: 148 - 151